Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Andrew James Aguirre, M.D., Ph.D.

Co-Author

This page shows the publications co-authored by Andrew Aguirre and Brian Wolpin.
Connection Strength

3.164
  1. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018 09; 8(9):1096-1111.
    View in: PubMed
    Score: 0.793
  2. Beyond the Front Line: Emerging Data for Maintenance Therapy in Pancreatic Cancer. J Clin Oncol. 2021 Oct 10; 39(29):3199-3206.
    View in: PubMed
    Score: 0.247
  3. Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. Cell Rep. 2021 Jul 13; 36(2):109367.
    View in: PubMed
    Score: 0.245
  4. Acquired Resistance to KRASG12C Inhibition in Cancer. N Engl J Med. 2021 06 24; 384(25):2382-2393.
    View in: PubMed
    Score: 0.245
  5. Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. Cell Rep. 2020 12 15; 33(11):108493.
    View in: PubMed
    Score: 0.236
  6. Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Clin Cancer Res. 2021 02 15; 27(4):1069-1081.
    View in: PubMed
    Score: 0.235
  7. Diabetes, Weight Change, and Pancreatic Cancer Risk. JAMA Oncol. 2020 10 01; 6(10):e202948.
    View in: PubMed
    Score: 0.233
  8. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet Med. 2019 01; 21(1):213-223.
    View in: PubMed
    Score: 0.199
  9. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncol. 2018 Mar 08; 4(3):e173420.
    View in: PubMed
    Score: 0.195
  10. Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma. Clin Cancer Res. 2021 Jul 20.
    View in: PubMed
    Score: 0.061
  11. Multiplexed single-cell transcriptional response profiling to define cancer vulnerabilities and therapeutic mechanism of action. Nat Commun. 2020 08 27; 11(1):4296.
    View in: PubMed
    Score: 0.058
  12. Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. Cancer Cell. 2020 08 10; 38(2):198-211.e8.
    View in: PubMed
    Score: 0.057
  13. Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2020 08; 29(8):1586-1595.
    View in: PubMed
    Score: 0.057
  14. Discovery of a selective inhibitor of doublecortin like kinase 1. Nat Chem Biol. 2020 06; 16(6):635-643.
    View in: PubMed
    Score: 0.056
  15. Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Cancer Discov. 2020 01; 10(1):104-123.
    View in: PubMed
    Score: 0.054
  16. iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer. Mol Cancer Ther. 2018 11; 17(11):2377-2388.
    View in: PubMed
    Score: 0.050
  17. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov. 2018 09; 8(9):1112-1129.
    View in: PubMed
    Score: 0.049
  18. Aspirin exerts high anti-cancer activity in PIK3CA-mutant colon cancer cells. Oncotarget. 2017 Oct 20; 8(50):87379-87389.
    View in: PubMed
    Score: 0.047
  19. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017 07 27; 547(7664):453-457.
    View in: PubMed
    Score: 0.046
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.